Study or Subgroup	Mean Difference	SE	Intervention Total	Control Total	Weight	Mean Difference IV, Random, 95% CI
Attar 2023 a	4.55	2.0865	20	12	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	20	13	3.3%	7.55 [3.20, 11.90]
Chodry F 2016	2.3	1.3419	51	41	5.5%	2.30 [-0.33, 4.93]
Delewi 2015	0.2	1.6358	59	52	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	27	27	4.2%	2.80 [-0.67, 6.27]
Fernandez-Aviles 2018	-0.9	1.6996	31	16	4.4%	-0.90 [-4.23, 2.43]
Haddad 2020	-2.49	2.997	17	20	2.1%	-2.49 [-8.36, 3.38]
Hare 2009	3.4	0.5841	20	14	8.0%	3.40 [2.26, 4.54]
Janssens 2006	1.2	1.8339	30	30	4.1%	1.20 [-2.39, 4.79]
Laguna 2018	0.48	2.7951	8	9	2.4%	0.48 [-5.00, 5.96]
Meyer GP 2009	0.8	2.78	30	30	2.4%	0.80 [-4.65, 6.25]
Ostovaneh 2021	0.1	0.7178	83	41	7.6%	0.10 [-1.31, 1.51]
Quyyumi 2011	1.5	3.6671	11	10	1.5%	1.50 [-5.69, 8.69]
Quyyumi 2017	-0.8	1.4253	72	79	5.2%	-0.80 [-3.59, 1.99]
Roman 2015 a	2	1.851	26	24	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	22	20	4.0%	2.00 [-1.65, 5.65]
Srimahachota S 2011	-1.7	2.9139	11	12	2.2%	-1.70 [-7.41, 4.01]
Surder 2016	1.07	1.6943	95	55	4.4%	1.07 [-2.25, 4.39]
Traverse 2010	-3.2	3.6334	30	10	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	53	26	3.6%	3.10 [-0.93, 7.13]
Traverse 2018	-1.9	2.6185	58	27	2.6%	-1.90 [-7.03, 3.23]
Whorle J 2010	-3.9	2.5291	29	13	2.7%	-3.90 [-8.86, 1.06]
Wollert 2017 a	0.5	1.7399	38	13	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	33	13	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	12	6	7.5%	4.30 [2.85, 5.75]
Total (95% CI)			**886**	**613**	**100.0%**	**1.37 [0.39, 2.35]**

Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%
Test for overall effect: Z = 2.73 (P = 0.006)



Supplementary Fig. 10A. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.8.1 time of assessment upto 6 months				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Subtotal (95% CI)			**30.3%**	**1.84 [-0.09, 3.77]**
Heterogeneity: Tau² = 3.88; Chi² = 14.38, df = 7 (P = 0.04); I² = 51%				
Test for overall effect: Z = 1.87 (P = 0.06)				
1.8.2 time of assessment upto 12 months				
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**52.0%**	**1.72 [0.41, 3.04]**
Heterogeneity: Tau² = 2.48; Chi² = 27.43, df = 10 (P = 0.002); I² = 64%				
Test for overall effect: Z = 2.57 (P = 0.01)				
1.8.3 time of assessment more than 12 months				
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Subtotal (95% CI)			**17.7%**	**-0.26 [-2.39, 1.88]**
Heterogeneity: Tau² = 1.59; Chi² = 6.44, df = 5 (P = 0.27); I² = 22%				
Test for overall effect: Z = 0.23 (P = 0.81)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: Chi² = 2.72, df = 2 (P = 0.26), I² = 26.6%				



Supplementary Fig. 10B. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by time of assessment. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.9.1 Mononuclear				
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**76.7%**	**0.94 [-0.11, 1.99]**
Heterogeneity: Tau² = 2.14; Chi² = 34.46, df = 19 (P = 0.02); I² = 45%				
Test for overall effect: Z = 1.75 (P = 0.08)				
1.9.2 Mesenchymal				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Subtotal (95% CI)			**19.2%**	**3.40 [0.62, 6.18]**
Heterogeneity: Tau² = 5.36; Chi² = 10.16, df = 3 (P = 0.02); I² = 70%				
Test for overall effect: Z = 2.40 (P = 0.02)				
1.9.3 Both				
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Subtotal (95% CI)			**4.1%**	**1.20 [-2.39, 4.79]**
Heterogeneity: Not applicable				
Test for overall effect: Z = 0.65 (P = 0.51)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: Chi² = 2.63, df = 2 (P = 0.27), I² = 24.1%				



Supplementary Fig. 10C. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by the type of cells administered. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.10.1 Intracoronary				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**89.6%**	**1.21 [0.16, 2.25]**
Heterogeneity: $Tau^2 = 2.92$; $Chi^2 = 46.03$, df = 22 (P = 0.002); $I^2 = 52\%$				
Test for overall effect: Z = 2.25 (P = 0.02)				
1.10.2 intravenous				
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Subtotal (95% CI)			**8.0%**	**3.40 [2.26, 4.54]**
Heterogeneity: Not applicable				
Test for overall effect: Z = 5.82 (P < 0.00001)				
1.10.3 direct intramyocardia				
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Subtotal (95% CI)			**2.4%**	**0.48 [-5.00, 5.96]**
Heterogeneity: Not applicable				
Test for overall effect: Z = 0.17 (P = 0.86)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: $Tau^2 = 2.79$; $Chi^2 = 54.27$, df = 24 (P = 0.0004); $I^2 = 56\%$				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: $Chi^2 = 8.04$, df = 2 (P = 0.02), $I^2 = 75.1\%$				



Supplementary Fig. 10D. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by the route of administration. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.11.1 Autologous				
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**73.2%**	**1.07 [0.01, 2.13]**
Heterogeneity: Tau² = 1.95; Chi² = 30.44, df = 19 (P = 0.05); I² = 38%				
Test for overall effect: Z = 1.98 (P = 0.05)				
1.11.2 Allogeneic				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Subtotal (95% CI)			**26.8%**	**2.57 [0.13, 5.01]**
Heterogeneity: Tau² = 5.60; Chi² = 23.18, df = 4 (P = 0.0001); I² = 83%				
Test for overall effect: Z = 2.06 (P = 0.04)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: Chi² = 1.21, df = 1 (P = 0.27), I² = 17.6%				



Supplementary Fig. 10E. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by autologous vs allogeneic stem cells. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.12.1 Administration < 24 hours				
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Subtotal (95% CI)			**9.5%**	**1.92 [-0.21, 4.04]**
Heterogeneity: Tau² = 0.00; Chi² = 0.23, df = 1 (P = 0.63); I² = 0%				
Test for overall effect: Z = 1.77 (P = 0.08)				
1.12.2 Administration 1 - 21 days				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**76.2%**	**1.51 [0.34, 2.68]**
Heterogeneity: Tau² = 3.24; Chi² = 43.44, df = 19 (P = 0.001); I² = 56%				
Test for overall effect: Z = 2.53 (P = 0.01)				
1.12.3 Administration > 21 days				
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Subtotal (95% CI)			**7.6%**	**0.10 [-1.31, 1.51]**
Heterogeneity: Not applicable				
Test for overall effect: Z = 0.14 (P = 0.89)				
1.12.4 Not mentioned				
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Subtotal (95% CI)			**2.2%**	**-1.70 [-7.41, 4.01]**
Heterogeneity: Not applicable				
Test for overall effect: Z = 0.58 (P = 0.56)				
1.12.5 >1 day				
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Subtotal (95% CI)			**4.4%**	**1.07 [-2.25, 4.39]**
Heterogeneity: Not applicable				
Test for overall effect: Z = 0.63 (P = 0.53)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: Chi² = 3.88, df = 4 (P = 0.42), I² = 0%				



Supplementary Fig. 10F. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by the administration time. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.44.1 < 100				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**74.7%**	**1.73 [0.62, 2.85]**
Heterogeneity: Tau² = 2.58; Chi² = 37.81, df = 19 (P = 0.006); I² = 50%				
Test for overall effect: Z = 3.05 (P = 0.002)				
1.44.2 ≥ 100				
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Subtotal (95% CI)			**25.3%**	**0.34 [-0.71, 1.39]**
Heterogeneity: Tau² = 0.00; Chi² = 3.80, df = 4 (P = 0.43); I² = 0%				
Test for overall effect: Z = 0.63 (P = 0.53)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: Chi² = 3.19, df = 1 (P = 0.07), I² = 68.7%				



Supplementary Fig. 10G. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by the sample size. LVEF was assessed using magnetic resonance imaging (MRI).

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI
1.52.1 < 500 million				
Attar 2023 a	4.55	2.0865	3.5%	4.55 [0.46, 8.64]
Attar 2023 b	7.55	2.2213	3.3%	7.55 [3.20, 11.90]
Chodry F 2016	2.3	1.3419	5.5%	2.30 [-0.33, 4.93]
Delewi 2015	0.2	1.6358	4.6%	0.20 [-3.01, 3.41]
Dill 2009	2.8	1.771	4.2%	2.80 [-0.67, 6.27]
Fernandez-Aviles 2018	-0.9	1.6996	4.4%	-0.90 [-4.23, 2.43]
Haddad 2020	-2.49	2.997	2.1%	-2.49 [-8.36, 3.38]
Hare 2009	3.4	0.5841	8.0%	3.40 [2.26, 4.54]
Janssens 2006	1.2	1.8339	4.1%	1.20 [-2.39, 4.79]
Laguna 2018	0.48	2.7951	2.4%	0.48 [-5.00, 5.96]
Ostovaneh 2021	0.1	0.7178	7.6%	0.10 [-1.31, 1.51]
Quyyumi 2011	1.5	3.6671	1.5%	1.50 [-5.69, 8.69]
Quyyumi 2017	-0.8	1.4253	5.2%	-0.80 [-3.59, 1.99]
Srimahachota S 2011	-1.7	2.9139	2.2%	-1.70 [-7.41, 4.01]
Surder 2016	1.07	1.6943	4.4%	1.07 [-2.25, 4.39]
Traverse 2010	-3.2	3.6334	1.6%	-3.20 [-10.32, 3.92]
Traverse 2011	3.1	2.0538	3.6%	3.10 [-0.93, 7.13]
Traverse 2018	-1.9	2.6185	2.6%	-1.90 [-7.03, 3.23]
Whorle J 2010	-3.9	2.5291	2.7%	-3.90 [-8.86, 1.06]
Subtotal (95% CI)			**73.6%**	**1.08 [-0.11, 2.26]**
Heterogeneity: Tau² = 3.14; Chi² = 41.74, df = 18 (P = 0.001); I² = 57%				
Test for overall effect: Z = 1.78 (P = 0.07)				
1.52.2 > 500 million				
Meyer GP 2009	0.8	2.78	2.4%	0.80 [-4.65, 6.25]
Roman 2015 a	2	1.851	4.0%	2.00 [-1.63, 5.63]
Roman 2015 b	2	1.8647	4.0%	2.00 [-1.65, 5.65]
Wollert 2017 a	0.5	1.7399	4.3%	0.50 [-2.91, 3.91]
Wollert 2017 b	1	1.799	4.2%	1.00 [-2.53, 4.53]
Yao 2009 a	4.3	0.7394	7.5%	4.30 [2.85, 5.75]
Subtotal (95% CI)			**26.4%**	**2.36 [0.77, 3.94]**
Heterogeneity: Tau² = 1.30; Chi² = 7.60, df = 5 (P = 0.18); I² = 34%				
Test for overall effect: Z = 2.91 (P = 0.004)				
Total (95% CI)			**100.0%**	**1.37 [0.39, 2.35]**
Heterogeneity: Tau² = 2.79; Chi² = 54.27, df = 24 (P = 0.0004); I² = 56%				
Test for overall effect: Z = 2.73 (P = 0.006)				
Test for subgroup differences: Chi² = 1.62, df = 1 (P = 0.20), I² = 38.2%				



Supplementary Fig. 10H. Forest plot showing the efficacy of stem cell therapy on the change in left ventricular ejection fraction (LVEF) from baseline, compared with control, stratified by dose administered. LVEF was assessed using magnetic resonance imaging (MRI).